TheraCryf (LSE:TCF) Current Accrued Expense : £0.00 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Current Accrued Expense?

TheraCryf's Current Accrued Expense for the quarter that ended in Sep. 2024 was £0.00 Mil.

TheraCryf Current Accrued Expense Historical Data

The historical data trend for TheraCryf's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Current Accrued Expense Chart

TheraCryf Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Current Accrued Expense

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

TheraCryf Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of TheraCryf's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

8EV:Germany

Address

Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG

Website

https://www.evgen.com

TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.